Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator

Cancer Investigation

Volumn 28, Issue 7, 2010, Pages 689-697

  Huang, Hong Yan ^a,b   Jiang, Ze Fei ^b   Li, Qing Xia ^a   Liu, Jia Yun ^a   Wang, Tao ^b   Zhang, Rui ^a   Zhao, Jing ^a   Xu, Yan Ming ^a   Bao, Wei ^a   Zhang, Yong ^a   Jia, Lin Tao ^a   Yang, An Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Breast cancer; Metastasis; Urokinase plasminogen activator

Indexed keywords

GELATINASE B; SMALL INTERFERING RNA; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA, SMALL INTERFERING; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77954812525     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357901003735642     Document Type: Article

References (36)

1. Guarneri, V.; Conte, P.F. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004, 31, S149-S161.
2. Vahdat, L.T. Clinical studies with epothilones for the treatment of metastatic breast cancer. Semin Oncol 2008, 35, 22-30.
3. Nozaki, S.; Endo, Y.; Nakahara, H.; Yoshizawa, K.; Ohara, T.; Yamamoto, E. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy. Anticancer Drugs 2006, 17, 1109-1117.
4. Duffy, M.J. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004, 10, 39-49.
5. Dass, K.; Ahmad, A.; Azmi, A.S.; Sarkar, S.H.; Sarkar, F.H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008, 34, 122-136.
6. Ploug, M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003, 9, 1499-1528.
7. Castellino, F.J.; Ploplis, V.A. Structure and function of the plasminogen/ plasmin system. Thromb Haemost 2005, 93, 647-654.
8. Lijnen, H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001, 86, 324-333.
9. Pulukuri, S.M.; Gondi, C.S.; Lakka, S.S.; Jutla, A.; Estes, N.; Gujrati, M.; Rao, J.S. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005, 280, 36529-36540.
10. Subramanian, R.; Gondi, C.S.; Lakka, S.S.; Jutla, A.; Rao, J.S. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol 2006, 28, 831-839.
11. Wang, Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 2001, 21, 146-170.
12. Gondi, C.S.; Lakka, S.S.; Yanamandra, N.; Siddique, K.; Dinh, D.H.; Olivero, W.C.; Gujrati, M.; Rao, J.S. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003, 22, 5967-5975.
13. Rao, J.S.; Gondi, C.; Chetty, C.; Chittivelu, S.; Joseph, P.A.; Lakka, S.S. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 2005, 4, 1399-1408.
14. Duffy, M.J.; Maguire, T.M.; McDermott, E.W.; O'Higgins, N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 1999, 71, 130-135.
15. Sidenius, N.; Blasi, F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003, 22, 205-222.
16. Sharp, P.A. RNAi and double-strand RNA. Genes Dev 1999, 13, 139-141.
17. Li, Q.X.; Zhao, J.; Liu, J.Y.; Jia, L.T.; Huang, H.Y.; Xu, Y.M.; Zhang, Y.; Zhang, R.; Wang, C.J.; Yao, L.B.; Chen, S.Y.; Yang, A.G. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther 2006, 5, 860-866.
18. Sumimoto, H.; Kawakami, Y. Lentiviral vector-mediated RNAi and its use for cancer research. Future Oncol 2007, 3, 655-664.
19. Tan, F.L.; Yin, J.Q. Application of RNAi to cancer research and therapy. Front Biosci 2005, 10, 1946-1960.
20. Fu, H.J.; Jia, L.T.; Bao, W.; Zhao, J.; Meng, Y.L.; Wang, C.J.; Yao, L.B.; Chen, S.Y.; Yang, A.G. Stable knockdown of estrogen receptor alpha by vector-based RNA interference suppresses proliferation and enhances apoptosis in breast cancer cells. Cancer Biol Ther 2006, 5, 842-847.
21. Wen, W.H.; Liu, J.Y.; Qin,W.J.; Zhao, J.;Wang, T.; Jia, L.T. ; Meng, Y.L.; Gao, H.; Xue, C.F.; Jin, B.Q.; Yao, L.B.; Chen, S.Y.; Yang, A.G. Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology 2007, 46, 84-94.
22. Choi, N.S.; Kim, S.H. Two fibrin zymography methods for analysis of plasminogen activators on gels. Anal Biochem 2000, 281, 236-238.
23. Kim, S.H.; Choi, N.S.; Lee, W.Y. Fibrin zymography: a direct analysis of fibrinolytic enzymes on gels. Anal Biochem 1998, 263, 115-116.
24. Ratnikov, B.I.; Deryugina, E.I.; Strongin, A.Y. Gelatin zymography and substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells overexpressing membrane type-1 matrix metalloproteinase. Lab Invest 2002, 82, 1583-1590.
25. Gupta, G.P.; Massague, J. Cancer metastasis: building a framework. Cell 2006, 127, 679-695.
26. Duffy, M.J.; McGowan, P.M.; Gallagher, W.M. Cancer invasion and metastasis: changing views. J Pathol 2008, 214, 283-293.
27. Van Der Burg, M.E.; Henzen-Logmans, S.C.; Berns, E.M.; van Putten, W.L.; Klijn, J.G.; Foekens, J.A. Expression of urokinasetype plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer 1996, 69, 475-479.
28. Rosenberg, S. The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective. Curr Pharm Des 2003, 9: 4p following Table of Contents.
29. Schweinitz, A.; Steinmetzer, T.; Banke, I.J.; Arlt, M.J.; Sturzebecher, A.; Schuster, O.; Geissler, A.; Giersiefen, H.; Zeslawska, E.; Jacob, U.; Krüger, A.; Stürzebecher, J. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004, 279, 33613-33622.
30. Arens, N.; Gandhari, M.; Bleyl, U.; Hildenbrand, R. In vitro suppression of urokinase plasminogen activator in breast cancer cells-a comparison of two antisense strategies. Int J Oncol 2005, 26, 113-119.
31. Sato, S.; Kopitz, C.; Schmalix, W.A.; Muehlenweg, B.; Kessler, H.; Schmitt, M.; Kr üger, A.; Magdolen, V. High-affinity urokinasederived cyclic peptides inhibiting urokinase/urokinase receptorinteraction: effects on tumor growth and spread. FEBS Lett 2002, 528, 212-216.
32. Miyagishi, M.; Hayashi, M.; Taira, K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 2003, 13, 1-7.
33. Zhang, Y.; Zhang, Y.F.; Bryant, J.; Charles, A.; Boado, R.J.; Pardridge, W.M. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004, 10, 3667-3677.
34. Ahmad, A.; Kong, D.;Wang, Z.; Sarkar, S.H.; Banerjee, S.; Sarkar, F.H. Down-regulation of uPA and uPAR by 3,3 diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J Cell Biochem 2009, 108, 916-925.
35. Kunigal, S.; Lakka, S.S.; Gondi, C.S.; Estes, N.; Rao, J.S. RNAimediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007, 121, 2307-2316.
36. Blasi, F.; Carmeliet, P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3, 932-943.